Seastar Medical Hldg Corp (ICU) Stock Price, Quote & News

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI)...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 427 8100

Website: seastarmedical.com

Address:

3513 Brighton Boulevard, Suite 410, Denver, United States

Aznwactrackstar Oct. 25 at 3:10 PM

$ICU Can someone check on Josh77? Hasnt posted since yesterday at 10:31PM.

1 · Reply

nonferrousguy Oct. 25 at 1:01 PM

$ICU Does anyone know when the earnings report will be released?

0 · Reply

CanadianDreamcast Oct. 25 at 7:13 AM

$ICU I lied sorry. Dude makes half a mill a year and hasn't bought one share. Let that sink in. Now I'm really done. #noschlorffinthegame

1 · Reply

CanadianDreamcast Oct. 25 at 3:52 AM

$ICU All 135,982 shares acquired by SeaStar Medical CEO Eric Schlorff were awarded to him, rather than purchased. SEC filings show the transactions were designated as "Grant/Award/Other Acquisition".....hasn't bought ONE SINGLE SHARE. All word No Deed. I'll quit complaining. Have a good weekend. Go Jays.

0 · Reply

josh77 Oct. 25 at 3:31 AM

$ICU What to Watch Full FDA approvals for adult indications Expanded CMS reimbursement beyond clinical trials Hospital adoption rates and real-world outcomes International expansion, especially in Europe and Asia

0 · Reply

josh77 Oct. 25 at 3:30 AM

$ICU Commercialization Strategy 🔗 Seamless Integration SCD therapy is designed to integrate directly into existing hemodialysis systems, making adoption easier for hospitals and ICUs. This reduces training and infrastructure barriers, accelerating uptake. 📦 Launch Milestones QUELIMMUNE therapy for pediatric AKI was commercially launched in July 2024, marking SeaStar’s transition to a revenue-generating company. Future launches will depend on trial outcomes and FDA approvals for adult indications like cardiorenal syndrome and systemic inflammatory response. 🤝 Strategic Partnerships SeaStar may pursue distribution partnerships with dialysis equipment providers or hospital networks to scale adoption. CMS coverage and FDA designations make it more attractive to potential collaborators.

0 · Reply

josh77 Oct. 25 at 3:30 AM

$ICU Reimbursement Outlook ✅ CMS Coverage Secured In May 2025, SeaStar received CMS (Centers for Medicare & Medicaid Services) approval to cover medical expenses for Medicare and Medicaid patients enrolled in its NEUTRALIZE-CRS trial for cardiorenal syndrome. This is a rare achievement—fewer than 100 clinical trials receive CMS coverage annually—signaling strong confidence in the therapy’s potential. 🧒 Pediatric AKI Pathway The pediatric version of SCD (QUELIMMUNE) received an Approvable Letter from the FDA in late 2023. Once fully approved, reimbursement for pediatric AKI treatment could follow quickly, especially given the Humanitarian Device Exemption (HDE) pathway, which simplifies access for rare conditions.

0 · Reply

josh77 Oct. 25 at 3:29 AM

$ICU SeaStar’s combination of strong clinical signals, regulatory momentum, and a massive market opportunity positions it as a potential disruptor in the ICU therapeutics space.

0 · Reply

josh77 Oct. 25 at 3:29 AM

$ICU SeaStar’s Edge: Mortality Impact: SeaStar’s pilot trial showed a 31% absolute reduction in mortality, which is substantial in ICU settings. Precision Immunomodulation: Targets activated neutrophils and monocytes, unlike broader cytokine filters. Pediatric Focus: QUELIMMUNE therapy fills a critical gap in pediatric AKI treatment.

0 · Reply

josh77 Oct. 25 at 3:29 AM

$ICU Clinical Trial Data Comparison Company / Therapy Key Trial Results Target Conditions Regulatory Status SeaStar Medical (SCD) 60-day mortality reduced to 50% vs 81% in control group (COVID-19 ICU trial) AKI, SIRS, COVID-19, Cardiac Surgery Multiple FDA Breakthrough Designations CytoSorbents (CytoSorb) Shown to reduce cytokine levels; mixed results on mortality in sepsis trials Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use ExThera Medical (Seraph 100) Case studies show pathogen clearance; limited large-scale trial data Sepsis, COVID-19 CE Mark, FDA Emergency Use Toraymyxin Improved survival in septic shock (Japan); limited Western trial data Septic shock Approved in Japan, EU

0 · Reply

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Sep 24, 2025, 4:22 PM EDT - 4 weeks ago

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Sep 23, 2025, 8:23 AM EDT - 4 weeks ago

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

Sep 4, 2025, 6:13 PM EDT - 7 weeks ago

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:22 AM EDT - 7 weeks ago

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

Aug 13, 2025, 4:05 PM EDT - 2 months ago

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 10:00 AM EDT - 2 months ago

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

Aug 6, 2025, 8:33 AM EDT - 2 months ago

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

Jul 31, 2025, 3:01 PM EDT - 3 months ago

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 22, 2025, 8:20 AM EDT - 3 months ago

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

Jul 16, 2025, 8:45 AM EDT - 3 months ago

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

Jul 10, 2025, 3:29 PM EDT - 3 months ago

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 8, 2025, 8:05 AM EDT - 3 months ago

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

Jul 2, 2025, 4:25 PM EDT - 4 months ago

SeaStar Medical Announces Positive Nasdaq Listing Determination

Jun 25, 2025, 8:05 AM EDT - 4 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

Jun 24, 2025, 9:05 AM EDT - 4 months ago

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

Jun 20, 2025, 12:10 PM EDT - 4 months ago

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

Jun 11, 2025, 8:25 AM EDT - 4 months ago

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

May 28, 2025, 8:05 AM EDT - 5 months ago

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

May 14, 2025, 9:49 PM EDT - 5 months ago

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 5 months ago

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:05 AM EDT - 5 months ago

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

May 7, 2025, 10:00 AM EDT - 6 months ago

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

Apr 30, 2025, 8:05 AM EDT - 6 months ago

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

Apr 8, 2025, 8:05 AM EDT - 7 months ago

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Mar 27, 2025, 4:05 PM EDT - 7 months ago

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 24, 2025, 5:30 PM EDT - 7 months ago

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:45 AM EDT - 7 months ago

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Feb 3, 2025, 4:05 PM EST - 9 months ago

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

Jan 22, 2025, 7:30 AM EST - 9 months ago

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

Jan 13, 2025, 8:30 AM EST - 10 months ago

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Jan 8, 2025, 8:30 AM EST - 10 months ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

Dec 23, 2024, 7:00 AM EST - 10 months ago

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

Dec 11, 2024, 6:30 AM EST - 11 months ago

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

Dec 4, 2024, 8:30 AM EST - 11 months ago

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

Nov 26, 2024, 8:00 AM EST - 11 months ago

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Nov 22, 2024, 8:30 AM EST - 1 year ago

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

Nov 15, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

Nov 13, 2024, 5:05 PM EST - 1 year ago

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

Oct 31, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Oct 25, 2024, 11:32 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

Oct 22, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

Oct 18, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

Oct 15, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

Oct 9, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

Sep 25, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

Aznwactrackstar Oct. 25 at 3:10 PM

$ICU Can someone check on Josh77? Hasnt posted since yesterday at 10:31PM.

1 · Reply

nonferrousguy Oct. 25 at 1:01 PM

$ICU Does anyone know when the earnings report will be released?

0 · Reply

CanadianDreamcast Oct. 25 at 7:13 AM

$ICU I lied sorry. Dude makes half a mill a year and hasn't bought one share. Let that sink in. Now I'm really done. #noschlorffinthegame

1 · Reply

CanadianDreamcast Oct. 25 at 3:52 AM

0 · Reply

josh77 Oct. 25 at 3:31 AM

0 · Reply

josh77 Oct. 25 at 3:30 AM

0 · Reply

josh77 Oct. 25 at 3:30 AM

0 · Reply

josh77 Oct. 25 at 3:29 AM

$ICU SeaStar’s combination of strong clinical signals, regulatory momentum, and a massive market opportunity positions it as a potential disruptor in the ICU therapeutics space.

0 · Reply

josh77 Oct. 25 at 3:29 AM

0 · Reply

josh77 Oct. 25 at 3:29 AM

0 · Reply

josh77 Oct. 25 at 3:28 AM

$ICU Market Potential SeaStar Medical projects a U.S. total addressable market (TAM) of $25 to $33 billion across five initial indications for its SCD therapy, pending FDA approvals. These include: Pediatric and adult acute kidney injury (AKI) Cardiorenal syndrome Hepatorenal syndrome End-stage renal disease (ESRD) Systemic inflammatory response in cardiac surgery patients This TAM reflects the high unmet need in ICU settings and the potential for SCD to become a standard adjunct to continuous renal replacement therapy (CRRT).

0 · Reply

josh77 Oct. 25 at 3:27 AM

$ICU SeaStar’s Edge: Precision Targeting: Unlike broad-spectrum cytokine filters, SCD focuses on specific immune cells, offering a more tailored approach. Multiple Breakthrough Designations: SeaStar has received at least four FDA Breakthrough Device Designations, signaling strong regulatory support. Pediatric Focus: QUELIMMUNE therapy for pediatric AKI is a unique niche with high unmet need.

0 · Reply

josh77 Oct. 25 at 3:27 AM

$ICU SeaStar’s SCD therapy stands out for its cell-specific immune modulation, which could offer better outcomes with fewer side effects compared to more generalized blood purification systems.

0 · Reply

josh77 Oct. 25 at 3:26 AM

$ICU Comparison to Competitors SeaStar’s SCD therapy is part of a niche but growing field of immunomodulatory extracorporeal therapies. Here’s how it compares: Company / Therapy Mechanism Target Condition(s) Regulatory Status Differentiator SeaStar Medical (SCD) Cell-directed immune modulation AKI, Cardiorenal, ESRD, SIRS FDA Breakthrough Device (multiple) Targets activated neutrophils/monocytes CytoSorbents (CytoSorb) Hemoadsorption of cytokines Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use Broad cytokine removal ExThera Medical (Seraph 100) Pathogen adsorption Sepsis, COVID-19 CE Mark, FDA Emergency Use Targets pathogens directly Toraymyxin Endotoxin adsorption Septic shock Approved in Japan, EU Specific to endotoxins

0 · Reply

josh77 Oct. 25 at 3:25 AM

$ICU QUELIMMUNE – Pediatric Acute Kidney Injury (AKI) Status: Approved under a Humanitarian Device Exemption (HDE) Launch: Commercially launched in July 2024 Designation: FDA Breakthrough Device Use: Treats critically ill children with AKI using SeaStar’s Selective Cytopheretic Device (SCD) therapy

0 · Reply

josh77 Oct. 25 at 3:25 AM

$ICU SCD Therapy – Adult Indications These indications use the same device with minimal modifications: Indication Status Acute Kidney Injury (AKI) Pivotal Trial Cardiorenal Syndrome Feasibility Study End-Stage Renal Disease (ESRD) Investigational Hepatorenal Syndrome (HRS) Investigational Systemic Inflammatory Response (Cardiac Surgery) Investigational

0 · Reply

josh77 Oct. 25 at 3:24 AM

$ICU Regulatory Acceleration Most pipeline products have received FDA Breakthrough Device Designation, which expedites development and review. SeaStar recently received two new Breakthrough Device Designations for treating systemic inflammatory response in adult and pediatric cardiac surgery patients

0 · Reply

josh77 Oct. 25 at 3:17 AM

$ICU Clinical Trial Results SeaStar recently reported positive early results for its QUELIMMUNE therapy in pediatric acute kidney injury (AKI) at the 5th International Symposium on AKI in Children. Upcoming data releases and trial updates—especially around 90-day survival rates and safety—could be pivotal

0 · Reply

josh77 Oct. 25 at 3:17 AM

$ICU FDA Regulatory Milestones The company’s Selective Cytopheretic Device (SCD) has Breakthrough Device Designation, which accelerates the FDA review process. Any movement toward FDA approval or expanded indications would be a major catalyst.

0 · Reply

josh77 Oct. 25 at 3:16 AM

$ICU Partnerships or Licensing Deals Any collaboration with larger medtech firms or hospitals could validate SeaStar’s technology and accelerate commercialization.

0 · Reply

josh77 Oct. 25 at 3:15 AM

$ICU The next earnings date is November 12, 2025. Investors will be watching for updates on: Cash runway Clinical progress Strategic outlook

0 · Reply

josh77 Oct. 25 at 3:14 AM

$ICU If all the above align, ICU could see a multi-bagger return, potentially trading in the $5–$10 range or higher, depending on market sentiment and revenue projections.

0 · Reply

Market Cap	21.50M
Revenue (ttm)	140,000.00
Net Income (ttm)	-24.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-17,735.71%
Debt to Equity Ratio	0.00

Volume	964,800
Avg Vol	2,323,722
Day's Range	N/A - N/A
Shares Out	34.10M
Stochastic %K	46%
Beta	-1.07
Analysts	Strong Sell
Price Target	$2.00